FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237370924> ?p ?o ?g. }

• W4237370924 endingPage "3857" @default.
• W4237370924 startingPage "3857" @default.
• W4237370924 abstract "Abstract Tetracyclines are broad-spectrum antibacterial agents. They inhibit bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. Besides tetracyclines’ potent antibacterial activity, there is accumulating in vitro and in vivo evidence that tetracycline derivatives, including COL-3, doxycycline, minocycline, and tigecycline (Škrtić, Cancer Cell (2011) 20(5): 10.015), also possess anticancer properties against both liquid and solid tumors. Several tetracyclines have been investigated in various cancer clinical trials. However, most of these human trials, including the recent phase 1 study of tigecycline in patients with acute myeloid leukemia (AML) (Reed, Cancer Med (2016) 5(11): cam4.845), have yielded disappointing results. We believe that the failure of tigecycline in the AML trial is due to its inadequate in vitro potency (single-to-double digits µM range). To identify more potent anticancer tetracyclines, we explored the anticancer, particularly antileukemia activities of novel tetracycline analogs created by the proprietary tetracycline total synthesis platform during our antibacterial drug discovery efforts. A collection of 2368 novel, structurally diverse tetracycline analogs was screened against the leukemia cell line THP-1 in an HTS format (386-well). From the 68 hits (2.9% hit rate) with sub-µM antiproliferation activity, five lead compounds derived from two sub-series were selected for further profiling, including TP-2846, which displayed one of the lowest GI50 values at 0.75 µM. As a comparison, tigecycline had a GI50 of 29 µM in the same assay. The five lead compounds were subsequently evaluated for antiproliferation activity in other liquid and solid tumor lines, including MV4-11 (0.020 µM), MOLT-4 (0.09 µM), K-562 (0.43 µM), HL-60 (0.37 µM), CCRF-CEM (0.067 µM), KG-1 (0.27 µM), Kasumi-1 (0.16 µM), U-87 (0.09 µM), HepG2 (1.6 µM), CCL-247 (0.26 µM), CCL-222 (0.48 µM), HTB-77 (0.26 µM), and CRL-1923 (6.2 µM) (values in parentheses are GI50 of TP-2846). TP-2846 and another lead compound were also screened against the NCI60 panels. TP-2846 demonstrated the highest overall antiproliferation potency against most cell lines tested and is 10-50 folds more potent than tigecycline. Using MV4-11 as the primary screening cell line, we subsequently evaluated and studied the structure-activity relationships of more than 170 analogs of TP-2846 with systematic variations at the C4, C7, and C8 positions of the tetracycline core. Although a number of new analogs displayed comparable antiproliferation activity in MV4-11, TP-2846 remains the most potent analog overall in vitro and was selected to be further profiled in vitro and in vivo (see accompanying abstracts “In vitro characterization of TP-2846: a novel tetracycline antileukemia agent” and “In vivo activities of TP-2846: a novel tetracycline antileukemia agent”). Citation Format: Cuixiang Sun, Peng Zhao, Diana Hunt, Kathryn Kerstein, Joseph Newman, Sara McKellip, Robert Bostwick, Jacques Dumas, Xiao-Yi Xiao. Discovery and structure-activity relationship studies of TP-2846: a novel tetracycline antileukemia agent [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3857." @default.
• W4237370924 created "2022-05-12" @default.
• W4237370924 creator A5014039480 @default.
• W4237370924 creator A5021558523 @default.
• W4237370924 creator A5035932065 @default.
• W4237370924 creator A5036748447 @default.
• W4237370924 creator A5042041170 @default.
• W4237370924 creator A5044710671 @default.
• W4237370924 creator A5049125764 @default.
• W4237370924 creator A5062551554 @default.
• W4237370924 creator A5069324271 @default.
• W4237370924 date "2019-07-01" @default.
• W4237370924 modified "2023-09-27" @default.
• W4237370924 title "Abstract 3857: Discovery and structure-activity relationship studies of TP-2846: a novel tetracycline antileukemia agent" @default.
• W4237370924 doi "https://doi.org/10.1158/1538-7445.am2019-3857" @default.
• W4237370924 hasPublicationYear "2019" @default.
• W4237370924 type Work @default.
• W4237370924 citedByCount "0" @default.
• W4237370924 crossrefType "journal-article" @default.
• W4237370924 hasAuthorship W4237370924A5014039480 @default.
• W4237370924 hasAuthorship W4237370924A5021558523 @default.
• W4237370924 hasAuthorship W4237370924A5035932065 @default.
• W4237370924 hasAuthorship W4237370924A5036748447 @default.
• W4237370924 hasAuthorship W4237370924A5042041170 @default.
• W4237370924 hasAuthorship W4237370924A5044710671 @default.
• W4237370924 hasAuthorship W4237370924A5049125764 @default.
• W4237370924 hasAuthorship W4237370924A5062551554 @default.
• W4237370924 hasAuthorship W4237370924A5069324271 @default.
• W4237370924 hasConcept C150903083 @default.
• W4237370924 hasConcept C185592680 @default.
• W4237370924 hasConcept C202751555 @default.
• W4237370924 hasConcept C207001950 @default.
• W4237370924 hasConcept C2777027569 @default.
• W4237370924 hasConcept C2777179404 @default.
• W4237370924 hasConcept C2778275353 @default.
• W4237370924 hasConcept C2780923616 @default.
• W4237370924 hasConcept C501593827 @default.
• W4237370924 hasConcept C55493867 @default.
• W4237370924 hasConcept C71924100 @default.
• W4237370924 hasConcept C86803240 @default.
• W4237370924 hasConcept C98274493 @default.
• W4237370924 hasConceptScore W4237370924C150903083 @default.
• W4237370924 hasConceptScore W4237370924C185592680 @default.
• W4237370924 hasConceptScore W4237370924C202751555 @default.
• W4237370924 hasConceptScore W4237370924C207001950 @default.
• W4237370924 hasConceptScore W4237370924C2777027569 @default.
• W4237370924 hasConceptScore W4237370924C2777179404 @default.
• W4237370924 hasConceptScore W4237370924C2778275353 @default.
• W4237370924 hasConceptScore W4237370924C2780923616 @default.
• W4237370924 hasConceptScore W4237370924C501593827 @default.
• W4237370924 hasConceptScore W4237370924C55493867 @default.
• W4237370924 hasConceptScore W4237370924C71924100 @default.
• W4237370924 hasConceptScore W4237370924C86803240 @default.
• W4237370924 hasConceptScore W4237370924C98274493 @default.
• W4237370924 hasIssue "13_Supplement" @default.
• W4237370924 hasLocation W42373709241 @default.
• W4237370924 hasOpenAccess W4237370924 @default.
• W4237370924 hasPrimaryLocation W42373709241 @default.
• W4237370924 hasRelatedWork W1593283480 @default.
• W4237370924 hasRelatedWork W1985435370 @default.
• W4237370924 hasRelatedWork W2020591349 @default.
• W4237370924 hasRelatedWork W2059063383 @default.
• W4237370924 hasRelatedWork W2102928406 @default.
• W4237370924 hasRelatedWork W2126035312 @default.
• W4237370924 hasRelatedWork W2142608535 @default.
• W4237370924 hasRelatedWork W4244601012 @default.
• W4237370924 hasRelatedWork W4385497594 @default.
• W4237370924 hasRelatedWork W1974052551 @default.
• W4237370924 hasVolume "79" @default.
• W4237370924 isParatext "false" @default.
• W4237370924 isRetracted "false" @default.
• W4237370924 workType "article" @default.